In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1
A common perception of genetic screening is that only individuals at high risk of certain diseases will be identified.
Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.
In 2024, an estimated 6 million pet dogs will be diagnosed with cancer in the United States. As someone who has lost several family dogs to cancer, I know how heartbreaking this diagnosis will be for each of those dogs’ owners.
Over 18 million people are diagnosed with cancer in the United States and approximately 50% report clinical levels of depression and/or anxiety, pain, and/or fatigue.1-2
I recently attended a dinner party where guests lamented the use of generative AI in schools. They asked questions like, “Will kids stop learning and plug all their essay prompts into ChatGPT?”
For many women, a confirmation of pregnancy tends to evoke numerous emotions: excitement, shock, nervousness, joy, gratitude, and sometimes, even surprise. It is a moment dreamed, prayed, and planned for—but not for all.
The initial foray into genomic sequencing two decades ago has led to the discovery of key driver mutations and spurred drug development, thereby transforming the management of imminently lethal diseases.
While overall cancer death rates have been dropping, the number of individuals being diagnosed with cancer has been going up, with younger patients increasingly affected.
CAR T-cell therapies have been used to treat cancer patients since 2011, but infection-related adverse events remain a significant hurdle. Often, fever is one of the earliest warning signs of clinical deterioration and a potentially life-threatening condition.
